Skip to main content
SpringerLink
Log in

The Treatment of Malignant Hypertension

  • Chapter
Topics in Clinical Pharmacology and Therapeutics

  • 182 Accesses

Abstract

Malignant hypertension is a severe elevation of blood pressure that results in acute renal damage. An American Medical Association Ad Hoc Subcommittee on Research has defined malignant hypertension as follows: “A clinical phase (of hypertension) rarely occurring de novo, more often appearing after the development of primary or secondary hypertension. It is characterized by established diastolic hypertension usually with a diastolic pressure greater than 140 mm Hg and by accelerated and progressive renal damage usually but not necessarily accompanied by papilledema and often by retinal hemorrhages or exudates, and given to early death in uremia unless the course is terminated along the way by complicating brain or heart damage” (1). Encephalopathy is a transient clinical state associated with malignant nephrosclerosis. It is characterized by headache, vomiting, convulsions, stupor or coma. It is a manifestation of cerebral edema and increased intracranial pressure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brust A A, Perera GA, Wilkins RW: Classification of types of hypertension. JAMA 166: 640–641, 1958.

    Google Scholar 

  2. Volhard F, Fahr T: Die Brightsche Nierenkrank-heit. Verlag Von Julius Springer, Berlin, pp 247–280, 1914.

    Google Scholar 

  3. Fahr T: Kurze Beiträge zür Frage der Nephroskele- rose. Deutsche Arch Für Klin Med 134: 366–389, 1920.

    Google Scholar 

  4. Fahr T: Über Nephroskelrose: Pathologioghe ana-tomic des Morbus Brightii. Harnorgane Mannliche Geschlechtsorgan. Verlag Von Julius Springer, Berlin, pp 933–958, 1934.

    Google Scholar 

  5. Giese J: The pathogenesis of hypertensive vascular disease. Munksgard, Copenhagen, 1966.

    Google Scholar 

  6. Bohle A, Grund K, Helmchen U, Meyer D: Primary malignant nephrosclerosis. Clin Sei Mol Med 51 (Suppl 3): 23s–25s, 1977.

    Google Scholar 

  7. Byrom FB: Tension and the artery: the experimental elucidation of pseudo-uremia and malignant neph-rosclerosis. Clin Sci Mol Med 51 (Suppl 3): 3s–11s, 1977.

    Google Scholar 

  8. Goldby FS, Bielin LJ: How an acute change in arterial pressure damages arterioles: electron microscopic changes during angiotensin infusion. Cardio- vasc Res 6: 569–684, 1972.

    Article  CAS  Google Scholar 

  9. Sokolow M, Perloff D: Five years survival of consec-utive patients with malignant hypertension treated with antihypertensive agents. Am J Cardiol 6: 858–863, 1960.

    Article  Google Scholar 

  10. Pohle JEF, Thurston H, Swales D: Hypertension with renal impairment: influence of intensive therapy. Q J Med 43: 569–581, 1974.

    Google Scholar 

  11. Woods JW, Blythe WB, Huffines WD: Management of malignant hypertension complicated by renal in-sufficiency: a follow-up study. N Engl J Med 291: 10–13, 1974.

    Article  PubMed  CAS  Google Scholar 

  12. Cordingly FT, Jones NF, Wing AJ, Hilton PJ: Re-versible renal failure in malignant hypertension. Clin Nephrol 14: 98–103, 1980.

    Google Scholar 

  13. Mroczek WJ, Davidov M, Gavrilovitch L, Finnerty FA: The value of aggressive therapy in the hypertensive patient with azotemia. Circulation 40: 893–904, 1969.

    Google Scholar 

  14. Perera G: Hypertensive vascular disease. J Chron Dis 1: 33–42, 1955.

    Article  PubMed  CAS  Google Scholar 

  15. Wagener HP, Keith NM: Cases of marked hypertension, adequate renal function and neuroretinitis. Arch Intern Med 34: 374–387, 1924.

    Google Scholar 

  16. Keith NM, Wagener HP, Kernohan JW: The syndrome of malignant hypertension. Arch Intern Med 41: 141–181, 1928.

    Google Scholar 

  17. Keith NM, Wagener HP, Barker NW: Some different types of essential hypertension; their course and prognosis. Am J Med Sci 197: 332–343, 1939.

    Article  Google Scholar 

  18. Sevitt LH, Evan DJ, Wrong OM. Acute oliguric renal failure due to accelerated (malignant) hypertension. Q J Med 40: 127–144, 1971.

    PubMed  CAS  Google Scholar 

  19. Tifft OP, Gavras H, Kershaw G, Gavras I, Brunner HR, Liang C, Chobanian A: Converting enzyme inhibition in hypertensive emergencies. Ann Intern Med 90: 43–47, 1979.

    PubMed  CAS  Google Scholar 

  20. Hodsman GG, Isles CG, Murray GD, Usherwood TP, Webb DJ, Robertson JIS: Factors related to first dose hypotensive effect of Captopril: prediction and treatment. Br Med J 286: 832–834, 1983.

    Article  CAS  Google Scholar 

  21. McAllister RG Jr: Guanethidine in hypertensive therapy: experience with an oral loading dose. J Clin Pharmacol 15: 771–778, 1975.

    PubMed  Google Scholar 

  22. Hertting J, Axelrod J, Patrick RW: Actions of bretylium and guanethidine on the uptake and release of [3H]-noradrenalin. Br J Pharmacol 18: 161–166, 1962.

    CAS  Google Scholar 

  23. Woosley RL, Nies AS: Drug therapy: guanethidine. N Engl J Med 295: 1053–1058, 1979.

    Google Scholar 

  24. Dranov J, Skyler JS, Gunnells JC: Malignant hypertension. Arch Intern Med 133: 791–801, 1974.

    Article  PubMed  CAS  Google Scholar 

  25. Manual of Medical Therapeutics, 23rd ed., Chapter 7. Little, Brown and Co, Boston, p 171, 1980.

    Google Scholar 

  26. Wilkinson EL, Backman H, Hect H: Cardiovascular and renal adjustments to a hypotensive agent (1- hydrazinophthalazine Ciba BA 5868;apresoline). J Clin Invest 31: 872–879, 1952.

    Article  PubMed  CAS  Google Scholar 

  27. Koch-Weser J: Drug therapy: diazoxide. N Engl J Med 294: 1271–1274, 1976.

    Article  PubMed  CAS  Google Scholar 

  28. Kanada SA, Kanada DJ, Hutchinson RA, Wu D: Angina-like syndrome with diazoxide therapy for hypertensive crisis. Ann Intern Med 84: 696–698, 1976.

    PubMed  CAS  Google Scholar 

  29. Anderson RJ, Hart GR, Crumpler CP, Reed WG, Matthews CA: Oral Clonidine loading in hypertensive urgencies. JAMA 246: 845–853, 1981.

    Google Scholar 

  30. Lowenthal DT: Pharmacokinetics of Clonidine. J Cardiovasc Pharmacol 2 (Suppl l): 529–537, 1981.

    Google Scholar 

  31. Velasquez MT, Rho J, Maronde RF, Barr J: Plasma Clonidine levels in hypertension. Clin Pharmacol Ther 35: 345–357, 1983.

    Google Scholar 

  32. Burns J, D’Angelo LJ: Complications of clonindine suppression test for pheochromocytoma. Letters: N Engl J Med 307: 756–757, 1982.

    Article  Google Scholar 

  33. Freis E: Reserpine in hypertension: present status. AFP 11 (No 6): 120–122, 1975.

    CAS  Google Scholar 

  34. Guazzi MD, Polese A, Fiorentini C, Bartorelli A, Motuzzi P: Treatment of hypertension with calcium antagonists; review Hypertens 5 (Suppl 2): 85–91, 1983.

    Google Scholar 

  35. Magometschnigg D: Acute hypotensive response to nifedipine. Hypertension 5 (No 2): 80–85, 1983.

    Google Scholar 

  36. Cotrell JE, Casthely P, Brodie JD, Patel K, Klein A, Turndorf H: Prevention of nitroprusside-induced cyanide toxicity with hydroxocobalamine. N Engl J Med 298: 809–811, 1978.

    Article  Google Scholar 

  37. Cummings AM, Brown J J, Frasher RR, Lever AT, Norton JS, Richards DA, Robertson JTS: Blood pressure lowering by incremental infusion of labetalol in patients with severe hypertension. Br J Clin Pharmacol 8: 359–364, 1979.

    PubMed  CAS  Google Scholar 

  38. Wilson DJ, Wallon JD, Vlachakis ND, Freis E, Vidt DG, Michelson EL, Langford HG, Flamenbaum W, Poland M: Intravenous labetalol in treatment of hypertension and hypertensive emergencies. Am J Med (Suppl Oct 17 ): 95–103, 1983.

    Google Scholar 

  39. Maronde RF, Robinson D, Vlachakis ND, Barr J, Chung M, Zampaglione N, Medakovic M: Study of single and multiple dose pharmacokinetic/phar-macodynamic modeling of antihypertensive effects of labetalol. Am J Med (Suppl Oct 17 ): 40–47, 1983.

    Google Scholar 

  40. Anderson J, Godfrey BE, Hill DM, Munro-Faure AD, Shelton J: A comparison of the effects of hydro-chlorothiazide and furosemide in the treatment of hypertensive patients. Q. J. Med 40: 541–560, 1971.

    PubMed  CAS  Google Scholar 

  41. Reigger G A, Steilner H, Haijduk K, Liebau G: Cap-topril in the long-term treatment of essential hyper-tension; changes in the renin-angiotensin-aldoste- rone system. Am J Cardiol 49: 1555–1557, 1982.

    Article  Google Scholar 

  42. VA Cooperative Study Group on Antihypertensive Agents: Propranolol in the treatment of essential hypertension. JAMA 237: 2303–2310, 1977.

    Google Scholar 

  43. Schumacker GE: Using pharmacokinetics in drug therapy. V. Contributions to developing dosage regi-mens for antihypertensive drugs. Am J Hosp Pharm 36: 1222–1226, 1979.

    Google Scholar 

  44. Laragh JH, Ulick S, Januszewicz V, Deming GB, Kelly WC, Lieberman S: Aldosterone secretion in primary and malignant hypertension. J Clin Invest 39: 1091–1106, 1960.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Robert F. Maronde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel C. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Clinical Pharmacology Section, University of Southern California, School of Medicine, Los Angeles, California, 90033, USA

    Robert F. Maronde (Professor of Medicine, Head) (Professor of Medicine, Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer-Verlag New York Inc.

About this chapter

Cite this chapter

Maronde, R.F., Robinson, D.C. (1986). The Treatment of Malignant Hypertension. In: Maronde, R.F. (eds) Topics in Clinical Pharmacology and Therapeutics. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-4864-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-4864-4_11

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-9336-1

  • Online ISBN: 978-1-4612-4864-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation